Physicochemical Properties of Oxaliplatin and Their Impact on Formulation Development
Abstract
The physical, chemical, and biological characteristics of active pharmaceutical ingredients are revealed by preformulation investigations, which are an essential stage in the drug formulation process. Oxaliplatin, a platinum-based anticancer drug used in colorectal cancer treatment, is the subject of this study preformulation. The main factors assessed are UV spectroscopy, melting point determination, partition coefficient, solubility, infrared spectroscopy, X-RD, and HPLC are examples of preformulation studies for antitumor agents. Oxaliplatin is appropriate for aqueous formulations due to its high water solubility and adequate stability. With a melting point of 200°C, the drug's crystalline nature was discovered by thermal research, indicating its stability under typical storage settings. Fourier-transform infrared spectroscopy compatibility studies showed positive interactions with excipients frequently seen in injectable formulations
Downloads
Metrics
References
Chaurasia, Gita. "A review on pharmaceutical preformulation studies in formulation and development of new drug molecules." Int J Pharm Sci Res 7, no. 6 (2016): 2313-2320.
Gopinath, R., and R. A. S. Naidu. "Pharmaceutical preformulation studies–current review." International Journal of Pharmaceutical and Biological Archives 2, no. 5 (2011): 1391-1400.
Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Annals of Oncology. 1998 Oct 1;9(10):1053-71.
Reis TA, Matos BN, Lima EM, Chaker JA, Gratieri T, Cunha-Filho MS, Gelfuso GM. Oxaliplatin preformulation studies for the development of innovative topical drug delivery systems. Journal of Thermal Analysis and Calorimetry. 2017 Dec;130:1671-81.
Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nature reviews Drug discovery. 2004 Jan 1;3(1).
Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. The Oncologist. 2004 Feb 1;9(1):8-12.
Pangeni R, Subedi L, Jha SK, Kweon S, Kang SH, Chang KY, Choi JU, Byun Y, Park JW. Improvements in the oral absorption and anticancer efficacy of an oxaliplatin-loaded solid formulation: pharmacokinetic properties in rats and nonhuman primates and the effects of oral metronomic dosing on colorectal cancer. International journal of nanomedicine. 2020 Oct 9:7719-43.
Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Therapeutics and clinical risk management. 2009 Mar 26:229-38.
Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Therapeutics and clinical risk management. 2009 Mar 26:229-38.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Vaishali Tandekar, Jatin Kumar Jamdar, Rukhmani Raman, Bishesar Sahu, Anjlai Sahu, Harish Sharma, Gyanesh Kumar Sahu
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
